Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Omar, Ayman I.

doi:10.3791/51638-v

Cited by 2 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 47 ] The actual standard of care for treating GBM, known as the “Stupp” protocol, consists of surgery when feasible, along with the administration of TMZ chemotherapy and concurrent radiation (60 Gy in 6 weeks), followed by adjuvant chemotherapy. [ 33 ] However, both PFS at six months and response rates at recurrence remain dismal (<20% and <10%, respectively). [ 47 ] As a matter of fact, several causes may interfere with chemotherapy response; definitely, one of the leading prognostic factors is the methylation of the MGMT promoter region.…”

Section: Use Of Ttfields In the Progressive Diseasementioning

confidence: 99%

Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives

Colamaria,

Leone,

Fochi

et al. 2023

Surgical Neurology International

View full text Add to dashboard Cite

Background: This review focuses on the recently published evidence on tumor treating fields (TTFields) administered alone or in combination with locoregional and systemic options for treating glioblastoma (GBM) in the past ten years. The aim is to critically summarize the novelty and results obtained with this innovative tool, which is becoming part of the armamentarium of neurosurgeons and neuro-oncologists. Methods: A comprehensive search and analysis were conducted on pivotal studies published in the past ten years. Furthermore, all completed clinical trials, whose results were published on clinicaltrials.gov, were examined and included in the present review, encompassing both recurrent (r) and newly diagnosed (n) GBM. Finally, an additional examination of the ongoing clinical trials was also conducted. Results: Recent trials have shown promising results both in patients with nGBM and rGBM/progressive (rGBM), leading to Food and Drug Administration approval in selected patients and the Congress of Neurological Surgeons to include TTFields into current guidelines on the management of GBM (P100034/S001-029). Recently, different randomized trials have demonstrated promising results of TTFields in combination with standard treatment of n- and rGBM, especially when considering progression-free and overall survival, maintaining a low rate of mild to moderate adverse events. Conclusion: Optimal outcomes were obtained in nGBM and progressive disease. A possible future refinement of TTFields could significantly impact the treatment of rGBM and the actual standard of care for GBM, given the better safety profile and survival effects.

show abstract

Section: Use Of Ttfields In the Progressive Diseasementioning

confidence: 99%

Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives

Colamaria,

Leone,

Fochi

et al. 2023

Surgical Neurology International

View full text Add to dashboard Cite

show abstract

“…In the recurrent setting, there exists no standard treatment approach. However, bevacizumab and TTFields therapy are the two FDA-approved treatment modalities 25,26 . The EF-11 phase III trial of TTFields monotherapy (with 20-24 h/day usage) versus active chemotherapy in patients with recurrent glioblastoma showed comparable overall survival, while toxicity and quality of life favored TTFields 27 .…”

Section: Ttfields Device and Treatment Optionsmentioning

confidence: 99%

“…A previous JoVE publication demonstrated the application of the first generation device using a plastic model of a human head 25 . Here, we demonstrate the application of the second-generation device on a glioblastoma patient undergoing treatment.…”

Section: Clinical Applicationmentioning

confidence: 99%

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Riley

San²,

Lok³

et al. 2019

JoVE

View full text Add to dashboard Cite

Glioblastoma is the most common and lethal form of brain cancer, with a median survival of 15 months after diagnosis and a 5 year survival rate of only 5% with current standard of care. Tumors often recur within 9 months following initial surgery, radiation and chemotherapy, at which point treatment options become limited. This highlights the pressing need for the development of better therapeutics to prolong survival and increase the quality of life for these patients.Tumor Treating Fields (TTFields) therapy was developed to take advantage of the effect of low frequency alternating electrical fields on cells for cancer therapy. TTFields have been demonstrated to disrupt cells during mitosis and slow tumor growth. There is also growing evidence that they act through stimulating immune responses within exposed tumors. The advantages of TTFields therapy include its noninvasive approach and increased quality of life compared to other treatment modalities such as cytotoxic chemotherapies. The Food and Drug Administration approved TTFields therapy for the treatment of recurrent glioblastoma in 2011 and for newly diagnosed glioblastoma in 2015. We report on the effects of TTFields during mitosis, the results of electric fields modeling, and proper transducer array placement. Our protocol outlines the clinical application of TTFields on a patient post-surgery, using the second-generation device.

show abstract

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Cited by 2 publications

References 12 publications

Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives

Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Contact Info

Product

Resources

About